Cys-MC-GGFG-Dxd

Overview

Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug- linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan ( HY-13631 ) derivative (DXd) ( HY-13631D ) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates ( ADC ), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Drug-Linker Conjugates for ADC

Product Information

• Catalog No.: HY-176415
• CAS No.: 3025787-83-8
• Molecular Formula: C55H63FN10O15S
• Molecular Weight: 1155.21
• Purity: 99.01%
• Storage: -20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Availability: In-stock

Source

Original product source